SOPHiA GENETICS (SOPH) Projected to Announce Earnings on Tuesday

SOPHiA GENETICS (NASDAQ:SOPH) is expected to be posting its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect SOPHiA GENETICS to announce earnings of ($0.1980) per share and revenue of $24.03 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. On average, analysts expect SOPHiA GENETICS to post ($0.77) EPS for the current fiscal year and ($0.31) EPS for the next fiscal year.

SOPHiA GENETICS Stock Up 2.3%

Shares of SOPH stock opened at $7.52 on Tuesday. The stock’s fifty day moving average price is $7.89 and its 200 day moving average price is $5.90. SOPHiA GENETICS has a 1-year low of $3.83 and a 1-year high of $8.98. The company has a market cap of $630.85 million, a price-to-earnings ratio of -6.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. BTIG Research raised their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, October 12th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Insider Buying and Selling

In related news, insider Zhenyu Xu sold 17,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00. Following the completion of the sale, the insider directly owned 590,887 shares in the company, valued at approximately $4,307,566.23. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Chairman Jurgi Camblong sold 40,172 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $326,598.36. Following the completion of the sale, the chairman owned 3,395,650 shares of the company’s stock, valued at $27,606,634.50. This trade represents a 1.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 250,662 shares of company stock worth $1,942,499 in the last 90 days. Insiders own 4.88% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a healthcare technology company that develops data-driven solutions for genomic medicine. Its cloud-based platform uses artificial intelligence, machine learning and advanced analytics to help healthcare organizations analyze and interpret complex biological and clinical data.

The company’s primary offering, the SOPHiA DDM platform, supports next-generation sequencing workflows, including data management, quality control, genomic analysis, variant interpretation and reporting.